MedAdvisor's trading update highlights

MedAdvisor (ASX:MDR) has issued a trading update for the first half of FY25. The company faced lower-than-expected vaccination rates in the US, affecting revenues. This led to a revenue shift from the first to the second half of the fiscal year for its US operations. Despite this, the Australian segment performed as expected.

Key takeaways from MedAdvisor's update

MedAdvisor's trading update for 1H FY25 shows a projected revenue decrease of 25-30% compared to 1H FY24, with EBITDA expected to remain positive. The company experienced revenue deferral in the US due to low vaccination rates but anticipates a strong second-half revenue boost due to a diversified pipeline. Australian operations are on track. CEO Rick Ratliff remains confident about achieving record second-half performance. MedAdvisor is focused on reducing revenue volatility by diversifying its customer base and pipeline. The company is financially prepared to support its strategic plans.

CEO's insights on current performance

We have made significant efforts in diversifying our pipeline and customer base, which we anticipate will drive increased revenue and mitigate revenue volatility from key clients. We are poised to achieve a record second-half revenue performance based on previous year results. The company is well-equipped financially to self-fund its strategic initiatives.